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ABSTRACT
Objectives: Different diagnostic algorithms for non-
acute heart failure (HF) exist. Our aim was to compare
the ability of these algorithms to identify HF in
symptomatic patients aged 80 years and older and
identify those patients at highest risk for mortality.
Design: Diagnostic accuracy and validation study.
Setting: General practice, Belgium.
Participants: 365 patients with HF symptoms aged
80 years and older (BELFRAIL cohort). Participants
underwent a full clinical assessment, including a
detailed echocardiographic examination at home.
Outcome measures: The diagnostic accuracy of 4
different algorithms was compared using an intention-
to-diagnose analysis. The European Society of
Cardiology (ESC) definition of HF was used as the
reference standard for HF diagnosis. Kaplan-Meier
curves for 5-year all-cause mortality were plotted and
HRs and corresponding 95% CIs were calculated to
compare the mortality risk predicting abilities of the
different algorithms. Net reclassification improvement
(NRI) was calculated.
Results: The prevalence of HF was 20% (n=74). The
2012 ESC algorithm yielded the highest sensitivity
(92%, 95% CI 83% to 97%) as well as the highest
referral rate (71%, n=259), whereas the Oudejans
algorithm yielded the highest specificity (73%, 95% CI
68% to 78%) and the lowest referral rate (36%,
n=133). These differences could be ascribed to
differences in N-terminal probrain natriuretic peptide
cut-off values (125 vs 400 pg/mL). The Kelder and
Oudejans algorithms exhibited NRIs of 12% (95% CI
0.7% to 22%, p=0.04) and 22% (95% CI 9% to 32%,
p<0.001), respectively, compared with the ESC
algorithm. All algorithms detected patients at high risk
for mortality (HR 1.9, 95% CI 1.4 to 2.5; Kelder) to 2.3
(95% CI 1.7 to 3.1; Oudejans). No significant
differences were observed among the algorithms with
respect to mortality risk predicting abilities.
Conclusions: Choosing a diagnostic algorithm for
non-acute HF in elderly patients represents a trade-off
between sensitivity and specificity, mainly depending
on differences between cut-off values for natriuretic
peptides.
INTRODUCTION
Early diagnosis of heart failure is important
to initiate treatment in a timely fashion, as it
may reduce mortality, hospitalisations and
healthcare costs.1 However, when access to
echocardiography is limited, such as primary
care, diagnosing heart failure in elderly indi-
viduals is challenging.1 2 Non-acute heart
failure with a gradual onset of symptoms is
especially often underdiagnosed or detected
in a later stage.3 4 Primary care physicians
are in need of a reliable diagnostic algorithm
that helps them to decide which older symp-
tomatic patients they must refer.
Different diagnostic rules and algorithms
to diagnose non-acute heart failure do exist
and all of them incorporate natriuretic pep-
tides.5–8 However, since natriuretic peptide
levels increase with age and are inﬂuenced
Strengths and limitations of this study
▪ Community studies involving elderly patients are
scarce, making this study particularly valuable.
▪ All variables needed to evaluate diagnostic per-
formance of the different rules and algorithms
were collected in the BELFRAIL study, including
a detailed description of echocardiographic
variables.
▪ No distinction was made between heart failure
with reduced ejection fraction and heart failure
with preserved ejection fraction as both are
important to detect.
▪ All patients with heart failure symptoms were
included, not just those suspected of heart
failure by their general practitioner (GP), since
suspicion is subjective and could lead to
misclassification.
▪ Clinical assessment was performed by the per-
sonal GP of each patient, which may have
increased heterogeneity, although GPs were
trained to limit this risk.
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by comorbidities, controversy remains regarding optimal
cut-off values among elderly individuals.9 10 Additionally,
Mant et al11 incorporated clinical characteristics in their
algorithm.6 This algorithm has not proven more beneﬁ-
cial than algorithms using only natriuretic peptides.12 13
Two new diagnostic algorithms have been published7 8
including an algorithm speciﬁcally designed for elderly
patients.8 However, the ability of these algorithms to
identify non-acute heart failure in symptomatic patients
aged 80 years and older has never been compared.
Furthermore, it is unknown whether these diagnostic
algorithms differ with respect to the identiﬁcation of
participants at high risk for mortality.
Therefore, an ‘intention-to-diagnose’ analysis14 was
performed within the BELFRAIL cohort and the ability
of the different diagnostic rules and algorithms to, ﬁrst,
conﬁrm the diagnosis of heart failure in very old symp-
tomatic patients and, second, to identify participants at
high risk for mortality.
METHODS
Study population
The BELFRAIL (BFC80+) study is a prospective, observa-
tional, population-based cohort study of participants aged
80 years and older living in three well-circumscribed areas
of Belgium. The study’s design, sampling methods and
cohort characteristics have been described previously.15 In
brief, a total of 29 general practice centres participated in
the BELFRAIL study. The participating centres were asked
to include patients aged 80 years and older in the cohort.
Only three exclusion criteria were used: (1) severe demen-
tia (known Mini-Mental State Examination (MMSE)
<15/30), (2) undergoing palliative care or (3) a medical
emergency like acute heart failure. Two sampling methods
for the recruitment of patients were used. Two general
practice centres were asked to include all eligible patients.
The remaining 27 centres were asked to include a
maximum of three consecutive patients during a 3-week
interval. In these 3 weeks, the general practitioners (GPs)
also planned their visit. This interval was repeated ﬁve
times, so every participating centre included a maximum
of 15 patients. Every interval of recruitment was started on
a different day to avoid selection bias. Between 2
November 2008 and 15 September 2009, 567 participants
were included in the BELFRAIL cohort. Three hundred
participants were included using the ﬁrst sampling
method, and 267 using the second sampling method. Out
of 567 patients, 365 (70%) presented with heart failure
symptoms such as dyspnoea (Medical Research Council
(MRC) ≥2), fatigue or ankle oedema. A detailed follow-up
regarding cause-speciﬁc mortality was collected from the
participants’ GPs until 5.2±0.25 years after baseline. The
causes of death were divided into cardiovascular and non-
cardiovascular. The BELFRAIL cohort is representative in
gender and age of the very elderly living in Belgium.15
STARD recommendations for reporting of diagnostic
accuracy studies were followed.16
Clinical assessment
Each GP recorded a full medical history and performed a
detailed, standardised clinical examination at baseline.
The analyses included questions regarding dyspnoea
(according to the MRC dyspnoea scale),17 fatigue,
orthopnoea, oedema of the lower extremities, wheezing
and loss of appetite. The clinical examination consisted
of a heart auscultation, a heart rate and breathing rate
measurement. The apical beat was palpated and
recorded when abnormal. Lung auscultation was per-
formed to detect crepitus. Jugular venous pressure ( JVP)
was measured and noted if elevated, and the presence of
hepatojugular reﬂux (HJR) and oedema of the lower
extremities was checked. Body mass index (BMI) was cal-
culated by a clinical research assistant based on a standar-
dised measurement of height and weight. The patients’
GPs reported a history of myocardial infarction and
important cardiac interventions such as percutaneous
transluminal coronary angioplasty, stenting or coronary
surgery. The Anatomic Therapeutic Chemistry classiﬁca-
tion system was used to register medication use.18 Data
regarding loop diuretics were used for the analyses.
The serum N-terminal probrain natriuretic peptide
(NT-proBNP) levels were measured using a
Dade-Dimension Xpand (Siemens, Deerﬁeld, Illinois,
USA). The coefﬁcient of variation ranged from 3.9% to
4.3%.
A 12-lead ECG was recorded by a clinical research
assistant at baseline using a QRS Universal ECG device
(QRS diagnostics, Plymouth, Minnesota, USA, http://
www.qrsdiagnostic.com). A single cardiologist blinded to
all other study results analysed each of the ECGs accord-
ing to the Minnesota Code Classiﬁcation System for
Electrocardiographic Findings and was asked to report
whether each patient’s ECG ﬁndings were completely
normal (yes or no).
Diagnostic algorithms
Four diagnostic algorithms were chosen because they
applied to patients aged 80 years or older with non-acute
heart failure in primary care. The 2012 European
Society of Cardiology (ESC) diagnostic algorithm5 and
the diagnostic rules proposed by Mant et al,6 Kelder
et al7 and Oudejans et al8 were studied (see online
supplementary appendix 1). The ESC algorithm
(NT-proBNP≥125 ng/mL or positive ECG) was studied
both with and without the inclusion of patients’ ECG
results.5 The diagnostic rule by Mant was evaluated by
considering direct referral for echocardiography of
patients with a history of myocardial infarction or basal
crepitus or men with ankle oedema. In the remaining
patients, referral for echocardiography was considered
for women without ankle oedema and NT-proBNP levels
above 620 pg/mL, women with ankle oedema and
NT-proBNP levels above 190 pg/mL and men with
NT-proBNP levels above 390 pg/mL.6 Using the diagnos-
tic rule of Kelder, heart failure was ruled out if the
summed score was <24 (<20% probability of heart
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failure).7 A score between 24 and 54 was considered
uncertain (between 20% and 70% probability of heart
failure). For patients with a score above 54, referral for
echocardiography was considered (>70% probability of
heart failure). The diagnostic rule of Oudejans consid-
ered heart failure unlikely if the summed score was 16
or less. Heart failure was considered likely with a score
of 32 or more and uncertain with a score between 16
and 32.8
Echocardiography
Echocardiograms were performed at baseline using a
commercially available portable system (CX50, Philips,
Andover, Massachusetts, USA) with M-mode, two-
dimensional and pulsed, continuous-wave and colour-
ﬂow Doppler capabilities. The echocardiograms were
performed at the participants’ homes by a single cardi-
ologist blinded to the patients’ clinical characteristics
and laboratory test results. A complete examination was
performed in accordance with the recommendations of
the American Society of Echocardiography and the
European Association of Echocardiography
(ASE-EAE).19 The methods, prevalences of the echocar-
diographic abnormalities and quality of the echocardio-
graphic images were described previously.20 Brieﬂy, left
ventricular (LV) systolic function was calculated using
Simpson’s biplane method.19 Systolic dysfunction was
deﬁned as an LV ejection fraction (LVEF) ≤50%. The
functions of the mitral valve and the aortic valve were
evaluated using colour Doppler echocardiography after
optimising the gain and Nyquist limit. Stenotic and
regurgitant valve diseases were evaluated using semi-
quantitative and quantitative methods recommended by
the ASE.21 22 Participants with prosthetic valves were
evaluated separately.21 Clinically relevant valve disease
was deﬁned as mitral stenosis of any severity, severe
aortic stenosis (aortic valve area <1 cm2), moderate or
severe mitral regurgitation, and moderate or severe
aortic regurgitation. Diastolic function was assessed
using mitral ﬂow velocities obtained via pulsed Doppler
and pulsed tissue Doppler at the level of the mitral
annulus.23 Additional apical and parasternal views were
also recorded to assess tissue velocity (colour tissue
Doppler). The ASA-EAE guidelines were used to assess
diastolic dysfunction.23
Reference standard
Heart failure deﬁned according to the ESC guideline
based on a combination of heart failure symptoms and
signs (table 1) and objective cardiac dysfunction was
used as the reference standard.5 Objective cardiac dys-
function included a LVEF≤50; clinically relevant valvular
heart disease and severe diastolic dysfunction, as used in
previous BELFRAIL publications.14 20
Data analysis
Continuous variables are presented either as means±SDs
or as medians and IQRs. Categorical data are presented
as frequencies and proportions. Baseline variables were
compared using the χ2 test or the independent
Student’s t-test to compare means, and the
Mann-Whitney U test to compare medians. p Values
below 0.05 were considered statistically signiﬁcant. The
diagnostic accuracy (the sum of true negatives and true
positives divided by the total number of participants) of
the different algorithms and rules for heart failure was
calculated using an intention-to-diagnose analysis. This
method, analogous to an ‘intention-to-treat’ analysis,
starts from a diagnostic intent, at any given moment, in
a population at risk. This means that all patients who are
at risk of a speciﬁc target condition should be involved
in the analyses, regardless of all previously known diag-
noses.14 Kaplan-Meier curves for all-cause mortality after
5 years were plotted for the different diagnostic algo-
rithms, with log-rank tests used for comparisons. HRs
and corresponding 95% CIs were calculated using Cox
proportional hazard models. The net reclassiﬁcation
improvement (NRI) was calculated for Oudejans’,
Kelder’s and Mant’s diagnostic rules and compared with
the ESC algorithm for the diagnosis of heart failure and
the prediction of 5-year all-cause and cardiovascular
mortality in order to measure and compare the ability of
the rules to detect participants at high risk for mortality.
All data analyses were performed using SPSS V.22.0 for
Windows (SPPS, Chicago, Illinois, USA).
RESULTS
In order to validate the existing rules, only participants
with heart failure symptoms such as dyspnoea (MRC≥2),
fatigue or ankle oedema were studied (n=365, 70%).
The mean age of the study participants was 85±3.8 years,
123 of whom were men (34%). A total of 40 patients
were institutionalised (11%). Heart failure was present
in 74 patients (20%).
Table 1 includes the distribution of the different vari-
ables used in the diagnostic algorithms and rules.
Patients with heart failure were older and presented
more often with orthopnoea, ankle oedema in men, an
irregular pulse, systolic heart murmur, elevated JVP or
HJR. Loss of appetite and a lower BMI, proposed as clin-
ical markers in the elderly (see online supplementary
appendix 1), were not statistically different across the
two patient groups.
Prediction of heart failure
All rules and algorithms exhibited a strong ability to
exclude heart failure. However, a high number of
unnecessary referrals were noted.
The 2012 ESC diagnostic algorithm
The 2012 ESC diagnostic algorithm proposes to refer
patients suspected of heart failure based on an abnor-
mal ECG or elevated natriuretic peptide levels
(NT-proBNP≥125 pg/mL; see online supplementary
appendix 1).5 However, the proportion of patients with
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an abnormal ECG was high in this population of very
elderly people (n=238, 65%). As a consequence, the
ESC algorithm with ECG results resulted in a higher
number of false positives (n=246, 77% of total referrals,
speciﬁcity 15%) and a similar sensitivity compared with
the ESC algorithm without ECG results. Therefore, the
ESC algorithm without ECG results was chosen for sub-
sequent analyses and considered an index test for the
calculation of the NRI (see online supplementary
appendix 1).
By applying the ESC algorithm without ECG results
(NT-proBNP≥125 pg/mL) to our study population, only
six patients with heart failure were missed, correspond-
ing to a sensitivity of 92%. However, 191 patients (74%
of total referrals) were referred despite the absence of
heart failure (speciﬁcity 34%; tables 2 and 3).
Table 1 Variables used in the diagnostic algorithms and rules according to the presence of heart failure
All
n=365
No heart failure
n=291
Heart failure
n=74 p Value*
Sociodemographic characteristics
Male gender, n (%) 123 (34) 93 (32) 30 (41) 0.16
Age, mean±SD 85±3.8 85±3.7 86±4.0 0.004†
80 years, n (%) 50 (14) 42 (14) 8 (11) 0.42
81–85 years, n (%) 178 (49) 151 (52) 27 (37) 0.018
86–90 years, n (%) 108 (30) 78 (27) 30 (41) 0.021
≥91 years, n (%) 29 (8) 20 (6.9) 9 (12) 0.13
Clinical characteristics
Symptoms
Nocturnal dyspnoea or orthopnoea, n (%) 29 (7.9) 18 (6.2) 11 (15) 0.014
Wheezing, n (%) 49 (13) 41 (14) 8 (11) 0.45
Loss of appetite, n (%) 51 (14) 42 (14) 9 (12) 0.62
Ankle oedema, n (%) 176 (48) 137 (47) 39 (53) 0.39
Men, n (%) 49 (13) 34 (12) 17 (23) 0.012
Women, n (%) 127 (35) 104 (36) 23 (31) 0.45
Signs
Displaced apical beat, n (%) 22 (6.0) 15 (5.2) 7 (9.5) 0.17
Basal crepitus lung, n (%) 56 (15) 46 (16) 10 (18) 0.63
Irregular pulse, n (%) 51 (14) 31 (11) 20 (27) <0.001
Systolic heart murmur, n (%) 131 (36) 81 (28) 50 (68) <0.001
Heart frequency, mean±SD 69±10 69±10 67±10 0.32†
Elevated jugular venous pressure, n (%) 46 (13) 26 (8.9) 20 (27) <0.001
Tachypnoea‡, n (%) 59 (16) 44 (15) 15 (20) 0.28
Hepatojugular reflux, n (%) 47 (13) 24 (8.2) 23 (31) <0.001
Peripheral oedema on clinical examination, n (%) 158 (43) 118 (41) 40 (54) 0.036
BMI (kg/m2), mean±SD 28±4.9 28±4.8 28±5.3 0.63†
<20, n (%) 15 (4.1) 12 (4.1) 3 (4.1) 0.98
20.0–24.9, n (%) 88 (24) 69 (24) 19 (26) 0.72
25.0–29.9, n (%) 137 (38) 111 (38) 26 (35) 0.63
30.0–34.9, n (%) 99 (27) 80 (28) 19 (26) 0.75
≥35.0, n (%) 26 (7.1) 19 (6.5) 7 (9.5) 0.38
Cardiovascular antecedents
MI, n (%) 46 (13) 34 (12) 12 (16) 0.29
MI, CABG or PCI, n (%) 70 (19) 49 (17) 21 (28) 0.024
ECG
Positive ECG§, n (%) 238 (65) 177 (63) 61 (85) 0.001
Medication
Loop diuretics, n (%) 80 (22) 54 (19) 26 (35) 0.002
NT-proBNP (pg/mL), median (IQR) 220 (110–593) 181 (100–394) 786 (350–1586) <0.001¶
<400, n (%) 240 (66) 219 (75) 21 (28) <0.001
400–2000, n (%) 102 (28) 63 (22) 39 (53) <0.001
>2000, n (%) 23 (6.3) 9 (3.1) 14 (19) <0.001
*χ2 test.
†Independent samples t-test.
¶Mann-Whitney test.
‡Breathing frequency >20/min.
§Abnormal ECG as read by a cardiologist.
BMI, body mass index; CABG, coronary artery bypass graft surgery; MI, myocardial infarction; NT-proBNP, N-terminal probrain natriuretic
peptide; PCI, percutaneous coronary intervention.
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The diagnostic rule of Oudejans et al
By applying the lower score of the diagnostic rule by
Oudejans et al (summed score >16), the highest number
of patients with HF was missed (n=19, a sensitivity of
74%), but the rule also corresponded to the lowest
number of unnecessary referrals (n=78, 59% of total
referrals) and consequently the highest speciﬁcity (73%;
tables 2 and 3).
Using the higher score of Oudejans’ rule (summed
score >32) resulted in only 29 false-positive cases (a spe-
ciﬁcity of 90%), of which 17 (59%) had at least one
other echocardiographic abnormality. However, sensitiv-
ity dropped to 42% (n=43 patients with missed heart
failure). Therefore, for subsequent analyses, the lower
score of Oudejans’ rule was used.
The rule of Oudejans yielded a signiﬁcant NRI of 21%
(95% CI 9% to 32%, p<0.001) in predicting heart
failure compared with the ESC diagnostic algorithm
(table 4). In Oudejans’ rule, an NT-proBNP cut-off of
400 pg/mL is used in addition to clinical characteristics
(see online supplementary appendix 1). However, the
comparison between NT-proBNP as a stand-alone test
(cut-off 400 pg/mL) and the full diagnostic rule of
Oudejans regarding both diagnostic and prognostic
accuracy yielded no signiﬁcant differences (data not
shown). Hence, the differences between the ESC algo-
rithm and the diagnostic rule of Oudejans could be
ascribed to differences in NT-proBNP cut-off values (125
vs 400 pg/mL).
The diagnostic rule of Kelder et al
By applying the higher score of Kelder’s rule (summed
score >54), 14 patients with heart failure were missed
(sensitivity 81%). False positives were noted in 124
patients (67% of total referrals), corresponding to a spe-
ciﬁcity of 57%.
Using the lower score of Kelder’s rule (summed score
≥24) led to zero false negatives (sensitivity 100%), but
only 18 patients were not referred in that case (speciﬁ-
city 6%). Therefore, for subsequent analyses, the higher
score of Kelder’s rule was used.
The rule of Kelder also yielded a signiﬁcant NRI of
12% (95% CI 0.7% to 22%, p=0.04) in predicting heart
failure compared with the ESC diagnostic algorithm
(table 4).
The diagnostic rule of Mant et al
Applying the diagnostic rule of Mant et al led to 15
patients with missed heart failure (sensitivity 80%) and
148 unnecessary referrals (71% of total referrals, speciﬁ-
city 59%). No signiﬁcant NRI was noted compared with
the ESC algorithm.
Five-year mortality predictions
During the 5-year follow-up period, 177 patients died
(49%), including 78 (44%) who died of cardiovascular
causes. There was no loss to follow-up for mortality. Of
the patients with heart failure, 61% died (n=45). The
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Table 3 Echocardiographic characteristics of patients according to the different decision rules and algorithms
ESC guideline HF
20124* Kelder et al diagnostic rule6† Oudejans et al diagnostic rule7‡
Mant et al clinical
decision rule5§
Non-referral
n=106
Referral
n=259
Non-referral
n=18
Uncertain
n=163
Referral
n=184
Non-referral
n=232
Uncertain
n=73
Referral
n=60
Non-referral
n=158
Referral
n=207
Heart failure, n=74
EF≤50, n (%) 1 (1.4) 14 (19) 0 (0) 1 (1.4) 14 (19) 4 (5.4) 4 (5.4) 7 (7.5) 2 (2.7) 13 (18)
Clinically relevant valvular disease,** n (%) 5 (6.8) 39 (53) 0 (0) 11 (15) 33 (45) 12 (16) 16 (22) 16 (22) 10 (14) 34 (46)
Severe diastolic dysfunction, n (%) 0 (0) 16 (22) 0 (0) 2 (2.7) 14 (19) 3 (4.1) 4 (5.4) 9 (12) 3 (4.1) 13 (18)
No heart failure, n=291
No echocardiographic abnormalities, n=102 42 (41) 60 (59) 8 (2.7) 55 (19) 39 (13) 84 (29) 10 (3.4) 8 (2.7) 56 (19) 46 (16)
Other echocardiographic abnormalities, n=189 58 (31) 131 (69) 10 (5.3) 94 (50) 85 (45) 129 (44) 39 (13) 21 (7.2) 87 (30) 102 (35)
RWMA, n (%) 9 (4.7) 19 (10) 0 (0) 14 (7.4) 14 (7.4) 19 (10) 6 (3.2) 3 (1.6) 10 (5.3) 18 (9.5)
Left atrial enlargement,†† n (%) 30 (16) 76 (40) 3 (1.6) 50 (27) 53 (28) 65 (34) 25 (13) 16 (8.5) 46 (24) 60 (32)
Left ventricular hypertrophy,‡‡ n (%) 15 (7.9) 21 (11) 3 (1.6) 20 (11) 13 (6.9) 30 (16) 5 (2.6) 1 (0.5) 25 (13) 11 (5.8)
Estimated pulmonary artery pressure
>30 mm Hg, n (%)
6 (4.6) 46 (35) 2 (1.1) 21 (11) 29 (15) 25 (19) 16 (12) 11 (8.5) 19 (15) 33 (25)
Moderate diastolic dysfunction, n (%) 21 (11) 46 (24) 6 (3.2) 32 (17) 29 (15) 51 (27) 11 (5.8) 5 (2.6) 35 (19) 32 (17)
*Referral, patients with non-acute onset suspected heart failure if NT-proBNP≥125 pg/mL.
†Non-referral, probability of heart failure <20%, <24 points; uncertain, probability of heart failure 20–70%, 24–54 points; referral, probability of heart failure >70%, >54 points.
‡Non-referral, geriatric patients with slow onset heart failure <16 points; uncertain, 16–32 points; referral >32 points.
§Referral, a history of myocardial infarction, basal crepitus, ankle oedema in a male OR female gender without ankle oedema if NT-proBNP >620 pg/mL, male gender without ankle oedema if
NT-proBNP>390 pg/mL, female gender with ankle oedema if NT-proBNP>190 pg/mL.
**Any grade of mitral stenosis, moderate/severe mitral or aortic regurgitation or severe aortic stenosis.
††Left atrial volume index≥34 mL/m².
‡‡Left ventricular mass index (LVMI)≥109 g/m² in women, LVMI≥132 g/m² in men.
EF, ejection fraction; ESC, European Society of Cardiology; HF, heart failure; RWMA, regional wall motion abnormality.
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proportion of cardiovascular deaths within this group
was 60% (n=27). HR for all-cause mortality of heart
failure was 1.6 (95% CI 1.2 to 2.3, p=0.004), and for car-
diovascular mortality 2.5 (95% CI 1.6 to 4.0, p<0.001).
The algorithms and diagnostic rules successfully identi-
ﬁed patients at risk for mortality (ﬁgure 1). HRs for all-
cause mortality ranged from 1.9 (95% CI 1.4 to 2.5;
Kelder) to 2.3 (95% CI 1.7 to 3.1; Oudejans), and from
1.7 (95% CI 1.0 to 2.6; Mant) to 2.9 (95% CI 1.9 to 4.5;
Oudejans) for cardiovascular mortality.
The improvements in mortality risk classiﬁcation of
the diagnostic rules of Kelder and Mant were only
minor compared with the ESC algorithm. The diagnos-
tic rule of Oudejans exhibited a larger degree of
improvement, particularly with respect to cardiovascular
mortality risk classiﬁcation, although the said improve-
ment was not statistically signiﬁcant (NRI 10% (95% CI
−3% to 22%, p=0.18; table 4).
DISCUSSION
The present study demonstrated that all diagnostic algo-
rithms have their limitations in symptomatic patients
aged 80 years and older. Therefore, choosing a diagnos-
tic algorithm for non-acute HF in elderly patients repre-
sents a trade-off between sensitivity and speciﬁcity,
mainly depending on differences between used cut-off
values for natriuretic peptides. The ESC algorithm
Table 4 Reclassification table and NRI* for the identification of heart failure and the prediction of 5-year mortality
All Reclassified up Reclassified down NRI (95% CI; p Value)
Kelder diagnostic rule7†
All-cause mortality
Dead, n (%) 177 10 (5.6) 44 (25) −0.19 (−0.27 to −0.11; <0.001)
Alive, n (%) 188 8 (3.7) 49 (26) −0.22 (−0.29 to −0.14; <0.001)
Total, n (%) 365 18 (4.9) 93 (25) 0.026 (−0.075 to 0.13; 0.65)
Cardiovascular mortality
Dead, n (%) 78 2 (2.6) 20 (26) −0.23 (−0.34 to −0.13; <0.001)
Alive, n (%) 287 16 (5.6) 73 (25) −0.20 (−0.31 to −0.19; <0.001)
Total, n (%) 365 18 (4.9) 93 (25) −0.03 (−0.15 to 0.09; 0.64)
Heart failure
Present, n (%) 80 2 (2.7) 10 (14) −0.11 (−0.21 to −0.02; 0.001)
Absent, n (%) 285 16 (5.5) 83 (29) −0.23 (−0.29 to −0.17; <0.001)
Total, n (%) 365 18 (4.9) 93 (25) 0.12 (0.007 to 0.22; 0.04)
Oudejans diagnostic rule8‡
All-cause mortality
Dead, n (%) 177 2 (1.1) 57 (32) −0.31 (−0.38 to −0.24; <0.001)
Alive, n (%) 188 1 (0.5) 72 (38) −0.38 (−0.45 to −0.31; <0.001)
Total, n (%) 365 3 (0.8) 129 (35) 0.07 (−0.03 to 0.17; 0.28)
Cardiovascular mortality
Dead, n (%) 78 1 (1.3) 22 (28) −0.27 (−0.38 to −0.16; <0.001)
Alive, n (%) 287 2 (0.7) 107 (37) −0.37 (−0.42 to −0.31; <0.001)
Total, n (%) 365 3 (0.8) 129 (35) 0.10 (−0.03 to 0.22; 0.18)
Heart failure
Present, n (%) 74 1 (1.3) 14 (19) −0.18 (−0.28 to −0.08; <0.001)
Absent, n (%) 291 2 (0.7) 115 (40) −0.39 (−0.45 to −0.33; <0.001)
Total, n (%) 365 3 (0.8) 129 (35) 0.21 (0.09 to 0.32; <0.001)
Diagnostic rule of Mant et al6
All-cause mortality
Dead, n (%) 177 12 (6.8) 32 (18) −0.11 (−0.18 to −0.04; 0.002)
Alive, n (%) 188 19 (10) 51 (27) −0.17 (−0.25 to −0.09; <0.001)
Total, n (%) 365 31 (8) 83 (23) 0.06 (−0.05 to 0.16; 0.32)
Cardiovascular mortality
Dead, n (%) 78 1 (1.3) 15 (19) −0.18 (−0.28 to −0.09; <0.001)
Alive, n (%) 287 30 (10) 68 (24) −0.13 (−0.19 to −0.07; <0.001)
Total, n (%) 365 31 (8) 83 (23) −0.05 (−0.17 to 0.06; 0.52)
Heart failure
Present, n (%) 74 2 (2.7) 11 (15) −0.12 (−0.22 to −0.03; 0.005)
Absent, n (%) 291 29 (10) 72 (25) −0.15 (−0.21 to −0.09; <0.001)
Total, n (%) 365 31 (8) 83 (23) 0.026 (−0.09 to 0.13; 0.66)
*Comparison between the rules of Kelder, Oudejans and Mant with the ESC 2012 diagnostic algorithm.
†Dichotomous variable with a cut-off >54.
‡Dichotomous variable with a cut-off >16.
ESC, European Society of Cardiology; NRI, net reclassification improvement.
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exhibited the highest sensitivity. However, implementing
this algorithm in this age group also resulted in high
referral rates. In contrast, the diagnostic rule of
Oudejans exhibited the highest accuracy with reasonable
referral rates (36%, n=133). The said rule was a superior
predictor of heart failure compared with the ESC algo-
rithm because of a strong gain in speciﬁcity, however, in
spite of a decrease in sensitivity. Furthermore, all algo-
rithms were able to identify patients at high risk for
5-year mortality.
The prevalence of heart failure in this population-
based cohort study of symptomatic elderly individuals
was 20%, as could be expected in this age group.24 The
2008 ESC algorithm with an NT-proBNP cut-off point of
400 pg/mL, the clinical decision rule of Mant and the
Dutch guideline (either NT-proBNP≥125 pg/mL or a
positive ECG) were validated by Oudejans et al12 in a
cohort of geriatric outpatients (patients referred to a
geriatrician on suspicion of HF). The prevalence of
heart failure was 45% in this cohort, resulting in higher
negative predictive values compared with this study
(Mant et al: 95% vs 91%), as well as higher positive pre-
dictive values (Mant et al: 62% vs 29%) and higher refer-
ral rates (Mant et al: 70% vs 57%). They concluded that
the 2008 ESC algorithm performed the best.12 However,
the Newcastle 85+ study demonstrated, in line with our
results, that both proposed NT-proBNP cut-off points
(125 and 400 pg/mL) had their limitations in an elderly
population. Their used reference standard was LV dys-
function.13 However, both studies agreed that algorithms
Figure 1 All-cause mortality risk stratification based on the diagnostic algorithms and rules. ESC, European Society of
Cardiology.
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using natriuretic peptide levels alone performed better
than the algorithms incorporating patients’ clinical
characteristics.12 13
For clinicians, the decision regarding the referral of
patients suspected of having a diagnosis of heart failure
will always be a trade-off between the potential beneﬁts
afforded by additional investigations and the burdens
the said investigations impose on affected patients.12 In
elderly patients, this choice is more difﬁcult, as the ben-
eﬁts may be smaller,5 25 26 and the burdens larger.
Therefore, large numbers of false positives should be
avoided, a scenario made possible with the use of the
diagnostic rule of Oudejans. On the other hand, effect-
ive treatments exist for heart failure characterised by
either a reduced ejection fraction or valvular heart
disease,5 25 highlighting the importance of reducing
false-negative cases, an area in which the ESC algorithm
excels. However, no differences in the identiﬁcation of
patients at high risk for 5-year mortality were observed
among the different rules and algorithms. Another difﬁ-
culty with an elderly population is the high prevalence
of echocardiographic abnormalities overall. Only
25–35% of the false-positive cases did not exhibit any
echocardiographic abnormalities. Additional research is
warranted regarding the clinical signiﬁcance of these
cardiac phenotypes among elderly patients.
NT-proBNP levels played a crucial role in all decision
rules and algorithms. Oudejans selected 400 pg/mL as a
cut-off point, whereas the ESC algorithm selected
125 pg/mL. Since the comparison between NT-proBNP
as a stand-alone test (cut-off 400 pg/mL) and the full
diagnostic rule of Oudejans regarding both diagnostic
and prognostic accuracy yielded no signiﬁcant differ-
ences, the distinction between the ESC algorithm and
the diagnostic rule of Oudejans could be ascribed to dif-
ferences in NT-proBNP cut-off values. The diagnostic
value of natriuretic peptides in heart failure has been
proved, even in the elderly.14 27 However, controversy
remains about optimal NT-proBNP cut-off values among
elderly patients.9 10 13 28–30 Previous studies have advo-
cated the use of age-dependent values.10 29 30 However,
these values were highly dependent on settings, popula-
tions and reference standards, and warrant further inves-
tigation. Although the beneﬁts of extensive diagnostic
rules with clinical variables were not proven, it is import-
ant to note that natriuretic peptide levels must never be
seen as a stand-alone test. A thorough clinical assess-
ment must always take precedence.
This was the ﬁrst comprehensive study to simulate and
compare the ability of the diagnostic rules of Oudejans
and Kelder to detect heart failure among symptomatic
elderly patients. Additionally, this was the ﬁrst study to
describe and compare the abilities of different algo-
rithms and clinical decision rules in identifying patients
at high risk for mortality. Moreover, community studies
involving elderly patients are scarce, which made our
data particularly valuable. However, a few limitations of
this study should be noted. First, heart failure was
chosen as the reference standard and deﬁned according
to the ESC deﬁnition of heart failure. No difference was
made between heart failure with reduced ejection frac-
tion and heart failure with preserved ejection fraction.
Although these entities have different therapeutic impli-
cations, both are important to detect. Debate is possible
about which echocardiographic abnormalities should be
regarded as objectiﬁed cardiac dysfunction. Therefore, a
nuanced presentation of all echocardiographic abnor-
malities present in the group of patients with and
without heart failure was given in table 3. Second, all
patients with heart failure symptoms were included, not
just those suspected of heart failure by their GPs. This
approach was chosen since suspicion of heart failure by
GPs is subjective and patients could be misclassiﬁed
based on suspicion. Third, the clinical assessment was
performed by each patient’s personal physician, which
may have increased the heterogeneity of our data.
However, all participating GPs were trained, and the
assessments of their patients were standardised to limit
the risk of heterogeneity as much as possible.15
In conclusion, in a cohort of symptomatic patients
aged 80 years and older, all diagnostic algorithms had
their limitations. Therefore, choosing a diagnostic algo-
rithm for non-acute HF in elderly patients represents a
trade-off between sensitivity (2012 ESC algorithm) and
speciﬁcity (diagnostic rule of Oudejans et al), depending
on differences between used cut-off values for natriuretic
peptides. The rules and algorithms were all able to
detect patients at high risk for mortality without signiﬁ-
cant differences between the rules. Further research is
warranted to identify strategies that optimise both sensi-
tivity and speciﬁcity in a heterogeneous population of
elderly patients.
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